IE 11 is a very old Browser and it`s not supported on this site

Consolidated statement of cash flow

in CHF 1 000

 

Notes

 

01.01.–31.03.2022

 

01.01.–31.03.2021

Cash flows from operating activities

 

 

 

 

 

 

Proceeds from sales of securities

 

4

 

246 903

 

199 408

Purchase of securities

 

4

 

(12 916)

 

(284 562)

Payments for services

 

 

 

(12 906)

 

(14 870)

Total cash flows from operating activities

 

 

 

221 081

 

(100 024)

 

 

 

 

 

 

 

Cash flows from financing activities

 

 

 

 

 

 

Dividend

 

 

 

(212 242)

 

(199 440)

Proceeds from sales of treasury shares

 

6

 

 

9 398

Purchase of treasury shares

 

6

 

(10 511)

 

Borrowing of bank loans

 

5

 

 

287 000

Interest payments

 

 

 

(248)

 

(43)

Total cash flows from financing activities

 

 

 

(223 001)

 

96 915

 

 

 

 

 

 

 

Foreign exchange difference

 

 

 

720

 

207

Change in cash and cash equivalents

 

 

 

(1 200)

 

(2 902)

 

 

 

 

 

 

 

Cash and cash equivalents at the beginning of the period

 

 

 

2 835

 

6 816

 

 

 

 

 

 

 

Cash and cash equivalents at the end of the period

 

 

 

1 635

 

3 914

The notes are an integral part of the condensed consolidated interim financial statements.

BB Biotech AG uses cookies to improve website usability and ensure the best possible user experience. Use of cookies & disclaimer